DUBLIN, Feb .18, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/6mq9sc/oral_proteins_and) has announced the addition of the "Oral Proteins and Peptides Market, 2015 - 2025" report to their offering.
The Oral Proteins and Peptides Market (2nd edition), 2015-2025 report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants.
One of the key objectives of this report is to understand the current and future state of oral proteins and peptide drugs market.
This was done by analyzing the following:
- Drugs currently available in the market and those under development
- Emerging technologies and key developments supporting the development of improved oral peptide delivery
- Development and likely sales potential of key marketed and pipeline oral proteins and peptides
The study provides a comprehensive analysis of the competition, partnerships and key players in the market. The research, analysis and insights presented in this report include the sales forecasts of emerging oral proteins / peptides which are currently either marketed or in late stage clinical development. Our study includes proteins such as antibodies and recombinant proteins including insulin, hormones, interferon etc. However, we have excluded enzymes from our analysis. The only enzyme covered in the report is Liprotamase from Eli Lilly. Liprotamase is a pancreatic enzyme replacement therapy product. The enzyme has been presented as it differs from competing marketed drugs for being non-porcine derived and lacking an enteric coating. We have also included a special section on Liprotamase.
One of the interesting features of this report is the inclusion of case studies on two cyclic oral peptides discovered before the year 2000. These two peptides, namely Sandimmune and DDAVP, act as a role model for the biotechnology and pharmaceutical companies for future innovation and development in this field.
Highlights:
- The market is characterized by the presence of 76 molecules in different phases of development.Four molecules are in the late stage clinical trials (phase III); of these, Oral Octreolin, Ostora and Plecanatide are likely to be made commercially available in 2016.
- Diabetes stands out among the indication groups for which various molecules are in investigational studies. Nearly 37% of the total molecules under research are being developed for diabetic disorders. Other prominent areas include gastric disorders andbone diseases.
- The market is not dominated by the presence of a big company or a group of companies. Several start-ups have led research efforts by developing the technologies that facilitate oral formulation of proteins and peptides.
- Prominent technologies include Axcess, GIPET, Peptelligence and Disulfide Rich Peptides; a number of oral proteins and peptides are based on one of these technologies.
- One of the primary drivers for growth in the industry is the rising venture capital interest and available funding from other avenues. In total, over the last 10 years, we identified total investment of close to USD 0.9 billion.
- The current crop of oral proteins and peptides is likely to benefit from early success of Linzess; combined, we expect it to be a multi-billion dollar market growing at an annualised rate of 30% over the coming decade.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. OVERVIEW AND MARKET BACKGROUND
5. DRUG PROFILES AND MARKET FORECAST
6. CASE STUDIES: LIPROTAMASE, SANDIMMUNE, DDAVP
7. TECHNOLOGY PLATFORMS
8. RECENT PARTNERSHIPS
9. VENTURE CAPITAL SUPPORT
10. SWOT ANALYSIS
11. CONCLUSION
12. APPENDIX 1: Tabulated Data
13. APPENDIX 2: List of Companies
Companies Mentioned
Following companies have been mentioned in the report: 30 of the 100+ Companies Featured
- Abbott Laboratories
- AbbVie
- Affilogic
- AIMM Therapeutics
- Alchemia
- Almirall S.A.
- Alnara Pharmaceuticals
- Amarillo Biosciences
- Anthera Pharmaceuticals
- Apollo Life Sciences
- Apotex
- Aptalis Pharma
- Arisgen
- Armour
- Astellas
- AstraZeneca
- Avaxia Biologics
- Barr Pharmaceuticals
- Biocon
- Biodel Inc.
- Bone Medical
- Bristol-Myers Squibb
- Cara Therapeutics
- Centocor Ortho
- Chiasma Pharmaceuticals
- Clinigene
- Cosmo Pharmaceuticals
- Diabetology Ltd.
- Diasome Pharma
- Digestive Care Inc.
Following Universities / Research Centres have been mentioned in this report:
- Elan Biotechnology Research Centre, Trinity College, Dublin
- Biomedical Advanced Research and Development Agency
- BioScience Innovation Centre
- Hadassit Medical Research
- Tianjin International Joint Academy of Biomedicine
- University of Southern California
- National Institute of Health
Following Venture Capital firms have been mentioned in this report: 30 of the 50 Plus Firms
- 7 Med Health Ventures
- Abingworth
- Aegis Capital Corporation
- Alta Biopharma Partners
- ARCH Venture Partners
- Ariel Southeast Angel Partners
- Ascent Biomedical Ventures
- Beacon Angels
- Boston Harbor Angels
- Cherrystone Angels
- Connecticut Innovations
- CT Innovations
- Devon Park BioVentures
- DNA Biomedical Solutions Ltd.
- F2 Ventures
- F3 Ventures
- Foresite Capital
- Fredric Price
- GGV Capital
- Golden Seeds
- Google Ventures
- Granite State Angels
- Great Point Partners
- Healthcare Private Equity
- InCubeBioVentures
- Jerusalem Global Ventures
- Johnson and Johnson Development Corporation
- LaunchPad Venture Group
- Life Sciences Fund Amsterdam
- Lilly Ventures
For more information visit http://www.researchandmarkets.com/research/6mq9sc/oral_proteins_and
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
